The present invention relates to the novel 8β-substituted estradienes of general formula (I), wherein R?2, R3, R6, R6", R7, R7", R14, R15, R15", R16, R16", R17 and R17"¿ have the meanings given in the description, R8 means a straight-chain or branched-chain, optionally partially or entirely halogenated alkyl or alkenyl radical having up to 5 carbon atoms, an ethynyl or prop-1-inyl radical and R11 means an n-pentyl- or n-hexyl radical. Said estradienes are used as pharmaceutical active agents which, in vitro, are provided with a higher affinity of estrogen receptor preparations of rat prostate than of estrogen receptor preparations of rat uterus and, in vivo, preferably act in a preferential contraceptive manner on the ovary without stimulating the uterus. The invention also relates to the production thereof, the therapeutic use thereof and pharmaceutical administration forms which contain the novel compounds. The invention further relates to the use of said compounds for male contraception and to the use of non-malignant or malignant proliferate diseases of the ovary, such as ovarian carcinoma or granulosa cell tumours for instance.